InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Saturday, 09/05/2020 10:45:10 PM

Saturday, September 05, 2020 10:45:10 PM

Post# of 233151
Interesting deal. This shows when BP sees potential they do the deal. NP has not been able convince any NP that Lero has potential to treat multiple indications


“AbbVie (ABBV) - Get Report and Chinese drugmaker (IMAB) - Get Report announced a collaboration on a cancer treatment candidate in a deal that could be worth more than $2 billion through incentives.

AbbVie will pay I-Mab $180 million up front as part of the deal to develop and collaborate on lemzoparlimab, a potential treatment for multiple cancers.

The drug is one of the company's leading drug candidates in I-Mab's pipeline and is designed to minimize the inherent binding of cancer cells to normal red blood cells which researchers say is critical to treating cancer. “
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News